



Interface Prescribing & New Therapies Subgroup



28th September 2010

Cilostazol (Pletal®) tablets

The Interface Prescribing & New Therapies Subgroup of the GMMMG discussed the above drug for the above indication. The recommendation of this subgroup is as follows*:

The New Therapies Subgroup of the GMMMG considered the use of cilostazol (Pletal®) for improvement of maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis.

The group does not recommend the use of cilostazol for intermittent claudication.

The group noted the modest efficacy and relative safety of cilostazol but consider that the patient population in clinical studies is not representative of the patient population in whom the treatment will be used in practice. This specifically relates to the lack of data on the safety and efficacy profile of cilostazol when co-administered with antiplatelet agents.

The group recommends that patients with intermittent claudication are adequately treated for secondary cardiovascular risk factors, and that non-pharmacological measures such as exercise programmes and smoking cessation are initiated.

Review date: September 2012

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.